Increased plasma endothelin-1 in the early hours of acute myocardial infarction
DJ Stewart,
G Kubac,
KB Costello,
and
P Cernacek
McGill Unit, Department of Medicine, McGill University, Montreal, Quebec, Canada.
Endothelin is a novel endothelium-derived vasoactive peptide with potent vasoconstrictor action in the coronary bed; however, its possible contribution to myocardial ischemia and infarction is not known. Plasma endothelin-1 concentration was measured with use of a radioimmunoassay in serial venous samples from 22 patients over a 72 h period after acute myocardial infarction (14 patients with uncomplicated infarction [group I] and 8 patients with hemodynamic or ischemic sequelae [group II]). Twenty-two normal subjects and seven patients with stable angina served as the control subjects. Endothelin-1 levels in patients with stable coronary disease were not different from those of normal subjects (0.62 +/- 0.56 and 0.76 +/- 0.38 pg/ml, respectively). In group I, plasma levels of endothelin-1 rose sharply after myocardial infarction, reaching a peak of 4.95 +/- 0.78 pg/ml at 6 h after the onset of chest pain (p less than 0.05 compared with values in control subjects) and returning rapidly toward the normal range by 24 h. Patients with complicated infarction (group II) demonstrated a similar rapid increase in plasma endothelin-1 to a peak value of 8.29 +/- 1.95 pg/ml; however, plasma endothelin-1 remained elevated in these patients, becoming significantly different from values in group I at 48 and 72 h. There was no correlation between peak increases in creatine kinase and peak endothelin-1 in either group, suggesting that the stimulus for elevation of endothelin-1 was not myocardial necrosis itself. Furthermore, left ventricular ejection fraction did not correlate with the increase in endothelin-1 in group I patients, whereas there was a significant inverse relation between ventricular function and plasma endothelin-1 in group II.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:

|
 |

|
 |
 
L.-W. Fu, Z.-L. Guo, and J. C. Longhurst
Endogenous endothelin stimulates cardiac sympathetic afferents during ischaemia
J. Physiol.,
July 1, 2010;
588(13):
2473 - 2486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. Stangos, I. K. Petropoulos, J.-A. C. Pournaras, E. Mendrinos, and C. J. Pournaras
The Vasodilatory Effect of Juxta-arteriolar Microinjection of EndothelinA Receptor Inhibitor in Healthy and Acute Branch Retinal Vein Occlusion Minipig Retinas
Invest. Ophthalmol. Vis. Sci.,
April 1, 2010;
51(4):
2185 - 2190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Marchant, Y. Dou, H. Luo, F. S. Garmaroudi, J. E. McDonough, X. Si, E. Walker, Z. Luo, A. Arner, R. G. Hegele, et al.
Bosentan Enhances Viral Load via Endothelin-1 Receptor Type-A-Mediated p38 Mitogen-Activated Protein Kinase Activation While Improving Cardiac Function During Coxsackievirus-Induced Myocarditis
Circ. Res.,
March 27, 2009;
104(6):
813 - 821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Tamareille, H. Achour, J. Amirian, P. Felli, R. J. Bick, B. Poindexter, Y. J. Geng, W. H. Barry, and R. W. Smalling
Left ventricular unloading before reperfusion reduces endothelin-1 release and calcium overload in porcine myocardial infarction.
J. Thorac. Cardiovasc. Surg.,
August 1, 2008;
136(2):
343 - 351.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kakoki, R. W. McGarrah, H.-S. Kim, and O. Smithies
Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury
PNAS,
May 1, 2007;
104(18):
7576 - 7581.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Niccoli, G. A. Lanza, S. Shaw, E. Romagnoli, D. Gioia, F. Burzotta, C. Trani, M. A. Mazzari, R. Mongiardo, M. De Vita, et al.
Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization
Eur. Heart J.,
August 1, 2006;
27(15):
1793 - 1798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. A. Khan
Role of Endothelin-1 in Acute Myocardial Infarction
Chest,
May 1, 2005;
127(5):
1474 - 1476.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-K. Yip, C.-J. Wu, H.-W. Chang, C.-H. Yang, T.-H. Yu, Y.-H. Chen, and C.-L. Hang
Prognostic Value of Circulating Levels of Endothelin-1 in Patients After Acute Myocardial Infarction Undergoing Primary Coronary Angioplasty
Chest,
May 1, 2005;
127(5):
1491 - 1497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, S. Di Biase, T. Russo, D. Labella, F. Zullo, G. Lombardi, and A. Colao
Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab.,
September 1, 2004;
89(9):
4588 - 4593.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Xia and M. Karmazyn
Obligatory Role for Endogenous Endothelin in Mediating the Hypertrophic Effects of Phenylephrine and Angiotensin II in Neonatal Rat Ventricular Myocytes: Evidence for Two Distinct Mechanisms for Endothelin Regulation
J. Pharmacol. Exp. Ther.,
July 1, 2004;
310(1):
43 - 51.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Inagaki, H. S. Hahn, G. W. Dorn II, and D. Mochly-Rosen
Additive Protection of the Ischemic Heart Ex Vivo by Combined Treatment With {delta}-Protein Kinase C Inhibitor and {epsilon}-Protein Kinase C Activator
Circulation,
August 19, 2003;
108(7):
869 - 875.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. O'Connor, W. A. Gattis, K. F. Adams Jr, V. Hasselblad, B. Chandler, A. Frey, I. Kobrin, M. Rainisio, M. R. Shah, J. Teerlink, et al.
Tezosentan in patients with acuteheart failure and acute coronary syndromes: Results of the randomized intravenous tezosentan study (ritz-4)
J. Am. Coll. Cardiol.,
May 7, 2003;
41(9):
1452 - 1457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. G. Hanratty, Y. Koyama, H. H. Rasmussen, G. I. C. Nelson, P. S. Hansen, and M. R. Ward
Exaggeration of nonculprit stenosis severity during acute myocardial infarction: implications for immediate multivessel revascularization
J. Am. Coll. Cardiol.,
September 4, 2002;
40(5):
911 - 916.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Mangiafico, L. S. Malatino, T. Attina, R. Messina, and C. E. Fiore
Exaggerated Endothelin Release in Response to Acute Mental Stress in Patients with Intermittent Claudication
Angiology,
July 1, 2002;
53(4):
383 - 390.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Basso, G. Thiene, M. Della Barbera, A. Angelini, M. Kirchengast, and S. Iliceto
Endothelin A-receptor antagonist administration immediately after experimental myocardial infarction with reperfusion does not affect scar healing in dogs
Cardiovasc Res,
July 1, 2002;
55(1):
113 - 121.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Mascia, L. Fedorko, D. J. Stewart, F. Mohamed, K. terBrugge, V. M. Ranieri, M. C. Wallace, and R. M. Pluta
Temporal Relationship Between Endothelin-1 Concentrations and Cerebral Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage Editorial Comment : Endothelin-1 in Vasospasm After SAH
Stroke,
May 1, 2001;
32(5):
1185 - 1190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Orem, C. Orem, Y. Alioglu, B. Vanizor, and C. Erdol
Effect of Coronary Angiography on Plasma Endothelin-1 and Nitric Oxide Concentrations
Angiology,
April 1, 2001;
52(4):
231 - 235.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Duru, M. Barton, T. F. Luscher, and R. Candinas
Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?
Cardiovasc Res,
February 1, 2001;
49(2):
272 - 280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Galiuto, A. N. DeMaria, U. del Balzo, K. May-Newman, S. F. Flaim, P. L. Wolf, M. Kirchengast, and S. Iliceto
Ischemia-Reperfusion Injury at the Microvascular Level : Treatment by Endothelin A-Selective Antagonist and Evaluation by Myocardial Contrast Echocardiography
Circulation,
December 19, 2000;
102(25):
3111 - 3116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. F. Luscher and M. Barton
Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs
Circulation,
November 7, 2000;
102(19):
2434 - 2440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ono, A. Matsumori, T. Shioi, Y. Furukawa, and S. Sasayama
Contribution of Endothelin-1 to Myocardial Injury in a Murine Model of Myocarditis : Acute Effects of Bosentan, an Endothelin Receptor Antagonist
Circulation,
October 26, 1999;
100(17):
1823 - 1829.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Battistelli, M. Billi, G. Manasse, A. Vittoria, F. Roviello, and S. Forconi
Behavior of Circulating Endothelin-1 in a Group of Patients with Acute Myocardial Infarction
Angiology,
August 1, 1999;
50(8):
629 - 638.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Tiret, O. Poirier, V. Hallet, T. A. McDonagh, C. Morrison, J. J. V. McMurray, H. J. Dargie, D. Arveiler, J.-B. Ruidavets, G. Luc, et al.
The Lys198Asn Polymorphism in the Endothelin-1 Gene Is Associated With Blood Pressure in Overweight People
Hypertension,
May 1, 1999;
33(5):
1169 - 1174.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Beyer, G. Slesak, T. Hovelborn, S. Kazmaier, S. Nerz, and H. M. Hoffmeister
Inotropic Effects of Endothelin-1 : Interaction With Molsidomine and With BQ 610
Hypertension,
January 1, 1999;
33(1):
145 - 152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Montalescot, F. Philippe, A. Ankri, E. Vicaut, E. Bearez, J. E. Poulard, D. Carrie, D. Flammang, A. Dutoit, A. Carayon, et al.
Early Increase of von Willebrand Factor Predicts Adverse Outcome in Unstable Coronary Artery Disease : Beneficial Effects of Enoxaparin
Circulation,
July 28, 1998;
98(4):
294 - 299.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Iannaccone, C. Letizia, S. Pazzaglia, E. M Vingolo, G. Clemente, and M. R Pannarale
Plasma endothelin-1 concentrations in patients with retinal vein occlusions
Br J Ophthalmol,
May 1, 1998;
82(5):
498 - 503.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. Thorin, P. Cernacek, and J. Dupuis
Endothelin-1 Regulates Tone of Isolated Small Arteries in the Rat : Effect of Hyperendothelinemia
Hypertension,
April 1, 1998;
31(4):
1035 - 1041.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Noll, R. R. Wenzel, S. de Marchi, S. Shaw, and T. F. Luscher
Differential Effects of Captopril and Nitrates on Muscle Sympathetic Nerve Activity in Volunteers
Circulation,
May 6, 1997;
95(9):
2286 - 2292.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H. Shimoyama, H. N. Sabbah, S. Borzak, M. Tanimura, S. Shevlyagin, G. Scicli, and S. Goldstein
Short-term Hemodynamic Effects of Endothelin Receptor Blockade in Dogs With Chronic Heart Failure
Circulation,
August 15, 1996;
94(4):
779 - 784.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
R. R. Wenzel, N. Duthiers, G. Noll, J. Bucher, U. Kaufmann, and T. F. Luscher
Endothelin and Calcium Antagonists in the Skin Microcirculation of Patients With Coronary Artery Disease
Circulation,
August 1, 1996;
94(3):
316 - 322.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. H. Traverse, D. Judd, and R. J. Bache
Dose-Dependent Effect of Endothelin-1 on Blood Flow to Normal and Collateral-Dependent Myocardium
Circulation,
February 1, 1996;
93(3):
558 - 566.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Setsuta, Y. Seino, Y. Tomita, J. Nejima, T. Takano, and H. Hayakawa
Origin and Pathophysiological Role of Increased Plasma Endothelin-1 in Patients with Acute Myocardial Infarction
Angiology,
July 1, 1995;
46(7):
557 - 565.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Seo and T. F. Luscher
ETA and ETB Receptors Mediate Contraction to Endothelin-1 in Renal Artery of Aging SHR : Effects of FR139317 and Bosentan
Hypertension,
April 1, 1995;
25(4):
501 - 506.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H. Takase, P. Moreau, and T. F. Luscher
Endothelin Receptor Subtypes in Small Arteries : Studies With FR139317 and Bosentan
Hypertension,
April 1, 1995;
25(4):
739 - 743.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H. Tomoda
Coronary Thrombolysis and Endothelin-1 Release
Angiology,
June 1, 1993;
44(6):
441 - 446.
[Abstract]
[PDF]
|
 |
|
|